Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neumega for TKI-associated thrombocytopenia in CML
NCT00493181Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2005
- Primary completion
- Jan 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of oprelvekin in Thrombocytopenia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Response at 2 years. Started Oct 2005; status: completed.
02
Drugs
oprelvekin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00493181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493181.